According to Benzinga Pro, Tonix Pharmaceuticals's peer group average for short interest as a percentage of float is 11.36%, which means the company has more short interest than most of its peers. Did ...

Tonix Pharmaceuticals (NASDAQ: TNXP) , a fully integrated biopharmaceutical company with marketed products and a robust development pipeline, announc ...

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biopharmaceutical company with marketed products and a ...

In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Unicycive Therapeutics (UNCY – Research Report), ...

Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, emphasized the company’s innovative efforts to improve patient access to necessary medications. He stated that TONIX ONE ...

Tonix Pharmaceuticals (TNXP) announced the launch of TONIX ONE, a fully-integrated digital platform designed to help patients better understand ...

Tonix Pharmaceuticals Holding Corp.’s TNXP share price has dipped by 11.27%, which has investors questioning if this is right time to buy.

Tonix Pharmaceuticals (NASDAQ: TNXP) is gaining attention as it advances TNX-102 SL, a non-opioid investigational therapy for fibromyalgia, toward po ...

CHATHAM, NJ / ACCESS Newswire / March 31, 2025 /This post was written and published as a collaboration between the in-house ...